Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: Any

statements set forth above that are not historical facts are forward-looking statements that

involve risks and uncertainties that could cause actual results to differ materially from

those in the forward-looking statements. Such factors include, but are not limited to, the

company’s ability to market existing and new products, ability to access to capital for

expansion, and changes from anticipated levels of sales, future national or regional

economic and competitive conditions, changes in relationships with customers,

dependence on our flagship product profits and other factors detailed from time to time in

the Company's filings with the United States Securities and Exchange Commission and

other regulatory authorities. The company undertakes no obligation to publicly update or

revise any forward-looking statements, whether as a result of new information, future

events or otherwise. This presentation was developed by the Company, is intended solely

for informational purposes and is not to be construed as an offer to sell or the solicitation

of an offer to buy the Company’s stock. This presentation is based upon information

available to the public, as well as other information from sources which management

believes to be reliable, but is not guaranteed by CHBT as being accurate nor does it purport

to be complete. Opinions expressed herein are those of management as of the date of publication and are subject to change without notice.

Safe Harbor Statement

2

Equity Snapshot

Listed on the OTC Bulletin Board

Symbol: CHBT

Price (11/16/07): $9.15

Market Cap: $156.3 mil

Shares Outstanding: 17.1 mil

Revenue (ttm): $34.8 mil

Net Income (ttm): $12.0 mi

l

EPS (ttm): $0.70

P/E (ttm): 13.0

P/S (ttm): 4.5

P/B (ttm): 5.2

EV/EBITDA (ttm): 7.2Insider / Institutional Ownership: 60.2% / 35.9%

Accountant: BDO McCabe Co. Ltd.Fiscal Year End: March 31 3

• Strong revenue and profit growth with high margins

• Proprietary technology creates sustainable, decisive competitive advantages

• Strong brand with significant franchise value

• Rising demand for China’s probiotics driven by increasing wealth and consumption of dairy products

• Entry into bulk additives market further propels growth

• Attractive valuation

Investment Highlights

4

Corporate Overview

• One of the largest probiotics suppliers in China

• Shining is one of the most recognized brands in Shanghai

• Proprietary technology offers significant cost and product quality advantages

• 266 employees

• 22 retail centers in China – 18 in Shanghai and four in Changchun (9/30/2007)

• Operates in retail and bulk additive spaces

Net Income

8.410.9

2006 2007 1H2007

21.6

30.6

Revenues

($ in Millions)

1H2008

17.713.5

4.5 5.5

Mission Statement: To become the dominant supplier of naturally occurring probiotic bacteria in China

5

What are Probiotics?

“Live microorganisms which, when administered in adequate amounts, confer a health benefit on the host”

– World Health Organization

• Benefits of probiotics– Improves health of G.I. tract

– Stimulates immune system

– Helps break down nutrients properly

– Reduces creation of toxins

– Reduces symptoms of lactose intolerance

– Decreases prevalence of allergy in susceptible individuals

– Reduces some risks associated with certain cancers

• 3 basic methods of delivery– Dairy products

– Dietary supplements (capsules, tablets, or powders)

– Other food and beverages Source: www.usprobiotics.org

* Sample: Bifido Bacteria, one kind of probiotic

6

Projected Rapid Growth

0

1000

2000

3000

4000

5000

6000

7000

MilkProducts

Animal Feed Capsules Other

CY 2006

CY 2010

Year Milk Products

Animal Feed

Capsule Form

Other Totals (mt)

2006 2,000 1,000 100 300 3,400

2010 6,500 2,500 600 1,000 10,600

• Chinese Probiotic Usage and Growth (Metric Tons)

Source: Domestic Probiotics Market Analysis and Forecast Report by Beijing Leadership Management Consulting Co. Limited

7

Market Snapshot

• Chinese affluence drives demand for health food– Demand for health food in China expected to reach $9.7B by 2010

(Source: Pacific Bridge Medical)

• Demand for milk/yogurt increasing significantly– Sales of yogurt drinks rose by 25% per year in 2005 and 2006– Chinese Bureau of Statistics forecasts tenfold increase in domestic dairy consum

ption, 2007-2015– U.S. banks investing in Chinese dairy industry

• Restricted use of antibiotics stimulates probiotic demand– Over-prescription of antibiotics in China– Chinese government is encouraging probiotics supplements to combat

antibiotics abuse

• China has limited probiotics production capacity– Current demand relies on imports from European manufacturers

8

Current Key Products

Shining Essence (63% of sales)

L. acidophilus & B. bifidium

Calms digestive system, enhances G.I. health and protects / strengthens liver function

Shining Signal (15% of sales)

Monascus rice and L. acidophilus

Reduces high blood pressure, high blood sugar levels and hyperlipidemia

Shining Golden Shield (9% of sales)

B. adolescentis & lentinusedodes

Enhances the body’s immune system

Shining Energy (8% of sales)

Vitamin C, L. Arginine, and other amino acids

Facilitates brain cell development and increases alertness

Product Key Components Uses

* As of Second Quarter ended September 30, 2007 9

New Product Development

• Additives for Yogurt – Essential to yogurt-based drinks

– One of the fastest-growing food pro

duct segments in China in 2005 and

2006

• Additives for Milk Powder– Commonly added to infant formula

– Improve digestion in babies

10

Distribution – Current and Planned

Supermarkets

Retailers / Pharmacies

Milk/Yogurt Products via Bulk Additives

Company-Owned Retail Centers

New Manufacturing Facility

11

Strategies for Growth

Shining Retail Center

• Leverage Shining brand; introduce new and complementary products

• Expand distribution network to 300 Shining brand retail centers by end of FY 2009

• Expand customer base to include bulk additive market

• Establish 150 mt / year production facility to take advantage of growing demand for probiotics

• Leverage our cost and quality advantage; develop export business in nutraceutical and bulk additive marketsmt = metric tons

12

• 60 retail centers by March 31, 2008

• 300 retail centers by March 31, 2009

• 550 square feet / center

• Initial investment about $40,000 per center

• Financed through operating cash flow

• Payback period < 1 year

Retail Expansion Strategy

13

• Launch “Shining Probiotics” for bulk additives line

• Produce bulk food additives for dairy and animal feed industries

• 150 mt / year production facility to be completed in 2008 CY

• Products sold directly to major international and domestic dairy and food manufacturers

• Revenue potential of new plant = $90 MM per year

Bulk Additive Strategy

CY = Calendar Year; mt = metric tons14

New Industry-Leading Facility

• Initial revenue opportunity at Phase I capacity = $90MM / year

• Phase 1 = 150 mt / year of production capacity

• Phase 2 = scalable to 300 mt / year

• Production yield allows company to sell for as little as one-sixth

competitors’ price while maintaining 70%+ gross margin

• Projected to be online in late 2008 CY

• The only probiotics plant cur

rently in development in Chi

na that will be able to meet t

he domestic demand for bul

k additives

CY = Calendar Year; mt = metric tons15

Proprietary Production Process

• Bacteria-Based Activation

• Bacteria-Based Cultivation

• Multistage Fermentation

• Bacteria Extraction

• Granule Emulsification

• Freeze-Drying

• Micro-Encapsulation

• Double-Aluminum Packaging

Leading edge production technology

• Fermentation: Very high production yield = low production cost and high margins

• Superior probiotic strands: Better functionality and product quality

• Micro-encapsulation: Very long shelf life

16

Mr. Song Jinan, Founder, Chairman and CEO• Founder and CEO since 1999; Masters degree in politics and economics f

rom Harbin Industrial University

Mr. Raymond Li, CFO• 20 years of finance experience in financial reporting, due diligence, M&A

activity, staff management and tax issues

Mr. Henry Tai, VP of Corporate Development• 20 years of experience in direct investments, corporate finance and

auditing in Australia, China, Hong Kong and the United Kingdom

Mr. Simon Yick, Non Executive Director• 20 years in corporate finance, direct investment and auditing

Dr. Chin Ji Wei, Non Executive Director• 20 years of academic experience in horticulture; authored 50+ papers;

awarded five patents, Science and Progressive AwardDr. Du Wen Min, Non Executive Director• Specialist in Study of Liver Disease; Deputy Director in charge of the Cent

re for Adverse Drug Reactions in Shanghai

Management and Director Team

17

Strong Financial Performance

Net Sales ($ in M illion)

14.4

21.9

30.6

13.517.7

FY 2005 FY 2006 FY 2007 1H 2007 1H 2008

CAGR = 45.7%

31.4% Gross Profit ($ in M illion)

0.0

5.0

10.0

15.0

20.0

25.0

FY '05 FY '06 FY '07 1H '08

66.0%

68.0%

70.0%

72.0%

74.0%

Gross Profit Gross Ma rgin

* For Fiscal Years Ended March 31

Net Income ($ in M illion)

4.55.55.5

10.9

8.4

FY 2005 FY 2006 FY 2007 1H 2007 1H 2008

CAGR = 47.3%

23.6%

18

Income Statement, 2006-2007

*The earnings per share figures reflect an increase in weighted-average shares related to the share

exchange transaction in March 2006.

For Fiscal Years Ended March 31

($ in thousands)

FY2007 06-07 % Change

FY2006 05-06 % Change

1H 2008

1H 2007

Net sales 30,610 40.0% 21,862 51.6% 17,700 13,470

Gross profit % 70.9% 70.5% 72.6% 70.2%

Operating income

14,931 22.5% 12,186 52.7% 7,704 6,448

Net income 10,905 30.5% 8,354 53.0% 5,510 4,457

EPS* $0.64 $4.90 $ 0.32 $ 0.26

19

Balance Sheet

March 31 September 30($ in thousands) 2007 2006 2007

Cash and cash equivalents 26,992 19,841 35,222

Total assets 44,580 33,427 53,057

Total liabilities 20,670 21,090 22,748

Stockholder’s equity 23,910 12,337 30,309

Current assets 41,897 31,833 46,582

Current ratio 2.0 1.5 2.3

20